Related Experiment Video
Updated: Jan 11, 2026
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management
Yuyang Zhang1, Haiming Kou1, Zhipeng Cheng1
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Dadao, Wuhan, China.
Introduction:
Natural killer/T-cell lymphoma (NKTL) is a rare disease that shows suboptimal responses to existing therapies. This study reports the efficacy of the P3-GemOx regimen compared to the traditional PP-GemOx regimen in advanced NKTL.
Methods:
Eleven patients received the P3-GemOx regimen [mitoxantrone hydrochloride liposome (Plm60) combined with PP-GemOx (anti-PD-1 antibody, pegaspargase, gemcitabine, and oxaliplatin)] every 3-4 weeks, with a median of 3 cycles (range: 1-4). Another eleven patients received the PP-GemOx regimen every 3-4 weeks, with a median of 4 cycles (range: 2-6). Treatment response was assessed using 18F-FDG-PET with CT or MRI.
Results:
All patients treated with P3-GemOx responded, with nine achieving complete remission (CR) and two partial remission (PR), yielding an overall response rate (ORR) of 100%. Seven of these patients underwent hematopoietic stem cell transplantation (HSCT). In the PP-GemOx group, the ORR was 63.6%, and no patients underwent HSCT. All adverse events were manageable and resolved.
Discussion:
The P3-GemOx regimen demonstrates superior efficacy over the PP-GemOx regimen in advanced NKTL.
